Rhythm Pharmaceuticalsの空売り状況は、投資家がRhythm Pharmaceuticalsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Rhythm Pharmaceuticals (NASDAQ:RYTM) 株価情報, 空売り情報

RHYTHM PHARMACEUTICALS INC

Rhythm Pharmaceuticals

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

Rhythm Pharmaceuticals, Inc. - Common Stock

Rhythm Pharmaceuticals Inc

Throughout the last three months, 12 analysts have evaluated Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>), offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">10</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Rhythm Pharmaceuticals, presenting an average target of $76.58, a high estimate of $94.00, and a low estimate of $66.00. This current average reflects an increase of 8.13% from the previous average price target of $70.82. 
<img src="https://www.benzinga.com/files/images/story/2025/1748541700_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of Rhythm Pharmaceuticals by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paul Matteis</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$94.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$72.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$68.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$92.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$66.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$91.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$66.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$72.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Paul Matteis</td>
<td>Stifel</td>
<td>Announces</td>
<td>Buy</td>
<td>$78.00</td>
<td>-</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$70.00</td>
<td>$69.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Rhythm Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Rhythm Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Rhythm Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Rhythm Pharmaceuticals's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/RYTM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Rhythm Pharmaceuticals analyst ratings.</a>
<h2>Get to Know Rhythm Pharmaceuticals Better</h2>
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
<h3>Financial Insights: Rhythm Pharmaceuticals</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Rhythm Pharmaceuticals's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 25.94% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Rhythm Pharmaceuticals's net margin excels beyond industry benchmarks, reaching -155.39%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -249.88%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Rhythm Pharmaceuticals's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -13.05%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.21, Rhythm Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

RYTM

12 Analysts Assess Rhythm Pharmaceuticals: What You Need To Know

Stifel analyst Paul Matteis maintains Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Buy and raises the price target from $78 to $94.

News

Price Target

Stifel Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $94

Biotech

General

Rhythm Pharmaceuticals Presents Data On Patients With Acquired Or Congenital Hypothalamic Obesity (N=35) Treated With Setmelanotide For Up To Nine Months In French Early-Access Program

In the preceding three months, 15 analysts have released ratings for Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>), presenting a wide array of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">13</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $73.2, a high estimate of $92.00, and a low estimate of $64.00. This current average reflects an increase of 5.32% from the previous average price target of $69.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1746648056_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Rhythm Pharmaceuticals among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$72.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$68.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$92.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$66.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$91.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$66.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$72.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Paul Matteis</td>
<td>Stifel</td>
<td>Announces</td>
<td>Buy</td>
<td>$78.00</td>
<td>-</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$70.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$81.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$64.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$64.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$64.00</td>
<td>$64.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Rhythm Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Rhythm Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Rhythm Pharmaceuticals's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Rhythm Pharmaceuticals's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/RYTM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Rhythm Pharmaceuticals analyst ratings.</a>
<h2>Discovering Rhythm Pharmaceuticals: A Closer Look</h2>
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
<h3>A Deep Dive into Rhythm Pharmaceuticals's Financials</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Rhythm Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 72.61% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Rhythm Pharmaceuticals's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -112.99% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Rhythm Pharmaceuticals's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -286.92%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -12.51%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Rhythm Pharmaceuticals's debt-to-equity ratio is below the industry average at 0.18, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Rhythm Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (15 Ratings)

Needham analyst Joseph Stringer maintains Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Buy and raises the price target from $66 to $72.

Needham Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $72

Earnings

Earnings Misses

Rhythm Pharmaceuticals Q1 EPS $(0.81) Misses $(0.70) Estimate, Sales $32.70M Miss $40.31M Estimate

ACAD

ACDC

ACRE

ACVA

ADMA

ADNT

ADTN

AIRG

ALNT

ALTG

ALTO

ALVO

AMPH

AMPL

AMRK

AMRN

AOSL

APLS

ARIS

ARMN

ASLE

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AVDX

AXON

AXTA

AZTA

BAND

BBDO

BBGI

BBSI

BGSF

Brighthouse Financial, Inc. - Common Stock

BLBD

BLMN

BLZE

BMBL

BRKR

BROS

BTMD

BXSL

BYND

CAPL

CCSI

CDLX

CENT

CENTA

CENX

CEVA

CIVI

CMTG

CNDT

COHR

Core Scientific, Inc. - Class A Common Stock

CORZ

CPRX

CRNC

CRNT

CSGS

CSTE

CTVA

CVNA

CYRX

Earnings Scheduled For May 7, 2025

These mid-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Agilon Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) shares jumped 36.87%. Bernstein analyst Amir Farahan upgraded the company from Market Perform to Outperform and raised the <a href="https://www.benzinga.com/quote/agl/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast from $3.3 to $8.5</a>.</li>
<li>Recursion Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) stock escalated 35.85% after the U.S. Food and Drug Administration news about animal testing.</li>
<li>Certara Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERT#NASDAQ">CERT</a>) stock upped 35.18%. The U.S. Food and Drug Administration announced a major shift in evaluating monoclonal antibody therapies and other drugs, emphasizing a <a href="https://www.benzinga.com//node/44764201" target="_blank" rel="noreferrer noopener">transition from traditional animal testing</a>.</li>
<li>AeroVironment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>) shares increased 31.06%, probably following President Trump&#8217;s decision to implement a 90-day pause on reciprocal <a href="https://www.benzinga.com/25/04/44720006/markets-take-off-as-trump-announces-90-day-tariff-pause-for-non-retaliating-nations-slaps-china-with-125-duty" target="_blank" rel="noreferrer noopener">tariffs for all countries except China</a>.</li>
<li>Sterling Infrastructure (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STRL#NYSE">STRL</a>) shares increased by 30.61%, probably following President Trump&#8217;s decision to implement a 90-day pause on reciprocal <a href="https://www.benzinga.com/25/04/44720006/markets-take-off-as-trump-announces-90-day-tariff-pause-for-non-retaliating-nations-slaps-china-with-125-duty" target="_blank" rel="noreferrer noopener">tariffs for all countries except China</a>.</li>
<li>Orla Mining Ltd. (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ORLA#AMEX">ORLA</a>) shares rose 29.35%.</li>
<li>Iamgold Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAG#NYSE">IAG</a>) shares were up 28.24%, probably as gold and silver gained amid macro uncertainty.</li>
<li>Sibanye Stillwater (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBSW#NYSE">SBSW</a>) shares were up 27.33% last week as gold and silver gained amid macro uncertainty.</li>
<li>Loar Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOAR#NYSE">LOAR</a>) stock upped 27.20%.</li>
<li>Rhythm Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) shares gained 26.84% after the company announced that the Phase 3 TRANSCEND<a href="https://www.benzinga.com//node/44670213" target="_blank" rel="noreferrer noopener"> trial met its primary endpoint</a>. Multiple analysts raised <a href="https://www.benzinga.com/quote/rytm/analyst-ratings" target="_blank" rel="noreferrer noopener">their price targets on the stock.</a></li>
<li>Telix Pharmaceuticals Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLX#NASDAQ">TLX</a>) stock surged 22.34%. The company selected Cardinal Health to distribute Gozellix, a PSMA-PET imaging agent for <a href="https://www.benzinga.com//node/44680639" target="_blank" rel="noreferrer noopener">prostate cancer, across the U.S</a>.</li>
</ol>
Photo via Shutterstock

Equities

Mid Cap

Movers

Trading Ideas

AVAV

CERT

LOAR

ORLA

RXRX

SBSW

STRL

These Mid-Cap Stocks Outshone The Market Volatility Last Week (Apr 7-Apr 11): Are These In Your Portfolio?

B of A Securities analyst Tazeen Ahmad maintains Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Buy and raises the price target from $63 to $68.

B of A Securities Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $68

U.S. stocks were higher, with the Dow Jones index surging over 1,300 points on Tuesday.
Shares of Marvell Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) rose sharply during Tuesday's session after Infineon Technologies agreed to acquire its Automotive Ethernet <a href="https://in.benzinga.com/25/04/44683383/marvell-plays-ai-hardball-divestiture-sparks-155-upside-says-analyst">Business for $2.5 billion in cash</a>.
The transaction includes Marvell&#8217;s Brightlane Automotive Ethernet portfolio and related assets. The company projected this segment to generate $225 million to $250 million in revenue in 2025, with a gross margin of around 60%.
Marvell Technology shares jumped 10.1% to $56.16 on Tuesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>agilon health, inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) shares jumped 31.8% to $5.60.</li>
<li>NextDecade Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXT#NASDAQ">NEXT</a>) gained 23.3% to $7.38 after the company announced a 20-year LNG sale and purchase agreement to supply 1.2 million tonnes per year to a subsidiary of Saudi Aramco.</li>
<li>Venture Global, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VG#NYSE">VG</a>) gained 21.4% to $8.50.</li>
<li>CorMedix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) shares rose 21.1% to $7.36 after the company issued first-quarter preliminary revenue guidance above estimates.</li>
<li>Pacira BioSciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) gained 16.1% to $26.60 after HC Wainwright &amp; Co. raised its price target on the stock from $48 to $65 and maintained a Buy rating.</li>
<li>Alignment Healthcare, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALHC#NASDAQ">ALHC</a>) jumped 14.9% to $20.48.</li>
<li>Uxin Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UXIN#NASDAQ">UXIN</a>) gained 14.7% to $3.9098.</li>
<li>Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) climbed 14.6% to $192.29.</li>
<li>Applied Optoelectronics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAOI#NASDAQ">AAOI</a>) rose 14% to $12.81.</li>
<li>ECARX Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECX#NASDAQ">ECX</a>) gained 14% to $1.14 after the company announced it increased its share repurchase program by $20 million to $40 million.</li>
<li>Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) rose 12.3% to $286.14 following a WSJ report indicating the Trump administration will increase Medicare Advantage rates.</li>
<li>Rhythm Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) gained 12.4% to $61.76. Canaccord Genuity analyst Whitney Ijem maintained Rhythm Pharmaceuticals with a Buy and raised the price target from $81 to $92.</li>
<li>Grab Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAB#NASDAQ">GRAB</a>) rose 12.4% to $3.9150.</li>
<li>Sandisk Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDK#NASDAQ">SNDK</a>) gained 12.4% to $35.40.</li>
<li>Western Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) rose 10% to $34.26.</li>
<li>AppLovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) gained 10% to $255.36.</li>
<li>CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) rose 8.5% to $69.29 after the company announced changes to management and Medicare increased advantage payment rates.</li>
<li>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) gained 7.9% to $105.39.</li>
<li>Shopify Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>) rose 7.8% to $85.05.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) gained 6.3% to $248.09.</li>
<li>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) rose 4.2% to $189.13. U.S. consumers are reportedly rushing to Apple stores to purchase new iPhones ahead of potential price hikes caused by President Donald Trump&#8217;s newly announced tariffs on Chinese imports.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44682968/how-to-earn-500-a-month-from-delta-air-lines-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Delta Air Lines Stock Ahead Of Q1 Earnings</a> </li>
</ul>
Photo via Shutterstock

Intraday Update

Markets

AAOI

AAPL

ALHC

CRMD

GRAB

MRVL

NVDA

PCRX

SHOP

SNDK

TSLA

UXIN

Marvell Technology, Nvidia, Tesla, Apple And Other Big Stocks Moving Higher On Tuesday

WIIM

Rhythm Pharmaceuticals shares are trading higher after multiple analysts raised their price targets on the stock.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Oppenheimer cut Autodesk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) price target from $350 to $300. Oppenheimer analyst Ken Wong maintained an Outperform rating. Autodesk shares closed at $243.62 on Monday. See how other analysts <a href="https://www.benzinga.com/quote/ADSK/analyst-ratings">view this stock</a>.</li>
<li>B of A Securities slashed the price target for Dollar Tree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) from $75 to $70. B of A Securities analyst Robert Ohmes maintained an Underperform rating. Dollar Tree shares closed at $72.84 on Monday. <a href="https://www.benzinga.com/quote/DLTR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird lowered Block, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) price target from $105 to $80. Baird analyst David Koning maintained an Outperform rating. Block shares closed at $50.47 on Monday. See how other analysts <a href="https://www.benzinga.com/quote/XYZ/analyst-ratings">view this stock</a>.</li>
<li>Wells Fargo cut the price target for Ralph Lauren Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>) from $275 to $240. Wells Fargo analyst Ike Boruchow upgraded the stock from Equal-Weight to Overweight. Ralph Lauren shares closed at $193.17 on Monday. <a href="https://www.benzinga.com/quote/RL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Citigroup cut the price target for Knight-Swift Transportation Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNX#NYSE">KNX</a>) from $53 to $48. Citigroup analyst Ariel Rosa upgraded the stock from Neutral to Buy. Knight-Swift Transportation shares closed at $39.30 on Monday. <a href="https://www.benzinga.com/quote/KNX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Barclays raised Rocket Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>) price target from $10 to $14. Barclays analyst Terry Ma upgraded the stock from Underweight to Equal-Weight. Rocket Companies shares settled at $14.66 on Monday. <a href="https://www.benzinga.com/quote/RKT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan cut Levi Strauss &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) price target from $19 to $17. JP Morgan analyst Matthew Boss upgraded the stock from Neutral to Overweight. Levi Strauss shares closed at $13.50 on Monday. <a href="https://www.benzinga.com/quote/LEVI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Jefferies increased Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) price target from $53 to $64. Jefferies analyst David Windley upgraded the stock from Underperform to Hold. Centene shares closed at $61.35 on Monday.  <a href="https://www.benzinga.com/quote/CNC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity raised the price target for Rhythm Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) from $81 to $92. Canaccord Genuity analyst Whitney Ijem maintained a Buy rating. Rhythm Pharmaceuticals shares settled at $54.96 on Monday. <a href="https://www.benzinga.com/quote/RYTM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo raised Ross Stores, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) price target from $140 to $150. Wells Fargo analyst Ike Boruchow upgraded the stock from Equal-Weight to Overweight. Ross Stores shares closed at $127.88 on Monday. <a href="https://www.benzinga.com/quote/ROST/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying ROST stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="452" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08091839/image-39-1024x452.png" alt="" class="wp-image-861945" style="width:682px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08091839/image-39-1024x452.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08091839/image-39-300x132.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08091839/image-39-768x339.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08091839/image-39.png 1398w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/news/earnings/25/04/44678688/dow-falls-for-3rd-session-amid-trumps-tariff-threats-as-apple-tesla-decline-greed-index-remains-in-extreme-fear-zone"> </a>
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44678688/dow-falls-for-3rd-session-amid-trumps-tariff-threats-as-apple-tesla-decline-greed-index-remains-in-extreme-fear-zone">Dow Falls For 3rd Session Amid Trump&#8217;s Tariff Threats As Apple, Tesla Decline: Greed Index Remains In &#8216;Extreme Fear&#8217; Zone</a></li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

ADSK

DLTR

LEVI

ROST

Ross Stores To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Tuesday

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Buy and raises the price target from $70 to $80.

HC Wainwright & Co. Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $80

Canaccord Genuity analyst Whitney Ijem maintains Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Buy and raises the price target from $81 to $92.

Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $92

Needham analyst Joseph Stringer reiterates Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Buy and maintains $66 price target.

Reiteration

Needham Reiterates Buy on Rhythm Pharmaceuticals, Maintains $66 Price Target

Wells Fargo analyst Derek Archila maintains Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Overweight and raises the price target from $80 to $91.

Wells Fargo Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $91

Rhythm Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) on Monday released topline results from the pivotal Phase 3 TRANSCEND trial evaluating setmelanotide, a melanocortin-4 receptor (MC4R) agonist, for the treatment of <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">acquired hypothalamic obesity</a>.
Acquired hypothalamic obesity is&nbsp;a rare, non-genetic form of obesity resulting from damage to the hypothalamus, the brain region controlling energy balance, often caused by tumors, surgery, or radiation, leading to rapid weight gain <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44663146/rhythm-pharmaceuticals-announces-pivotal-phase-3-transcend-trial-meets-primary-endpoint-with-19-8-" rel="noreferrer noopener">and metabolic complications</a>.
The global trial met its primary endpoint with a statistically significant and clinically meaningful reduction in body mass index (BMI) with setmelanotide in adult and pediatric patients versus placebo.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42627167/rhythm-pharmaceuticals-obesity-treatments-target-less-crowded-space-analyst-sees-long-term-potential" rel="noreferrer noopener">Rhythm Pharmaceuticals&#8217; Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential</a>
Highlights from the topline data include:
<ul>
<li>-19.8% placebo-adjusted difference in BMI reduction (N=120).</li>
<li>The primary endpoint of mean BMI reduction was -16.5% from baseline for all patients on setmelanotide therapy (n=81) compared with +3.3% BMI change for patients on placebo (n=39) at 52 weeks.</li>
<li>80% of patients on setmelanotide achieved a BMI reduction of 5% or greater at 52 weeks.</li>
<li>-19.2% placebo-adjusted BMI reduction was achieved in adult patients (n=49) and -20.2% in patients younger than 18 (n=71) at 52 weeks.</li>
</ul>
The company says the global Phase 3 TRANSCEND trial is believed to be the largest and longest placebo-controlled trial to evaluate therapy for patients with acquired hypothalamic obesity. The double-blinded, 52-week trial enrolled 120 patients.
Clinically meaningful improvements were observed across key secondary endpoints at week 52, including:
<ul>
<li>83% of patients on setmelanotide therapy achieved 5% or greater reduction in BMI (n=33 patients 18 or older) or BMI Z-score reduction of 0.2 or greater points (n=48 patients younger than 18).</li>
<li>-1.4 placebo-adjusted mean change in the weekly average of the daily maximal hunger score for patients 12 years old or older (n=81) (p=0.003).</li>
</ul>
No new safety signals with setmelanotide were observed, in line with setmelanotide&#8217;s well-established and well-understood safety profile. Consistent with prior clinical experience, setmelanotide was generally well tolerated in the TRANSCEND study.
The most common treatment-emergent adverse events (affecting &gt;20% of participants) were nausea, vomiting, diarrhea, injection site reaction, skin hyperpigmentation, and headache. No serious adverse events leading to study discontinuation were reported.
Price Action: RYTM stock is up 15.60% at $54.27 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44651786/lamb-weston-may-keep-cutting-prices-to-win-back-market-share-but-demand-recovery-remains-uncertain-says-analyst" target="_blank" rel="noreferrer noopener">Lamb Weston May Keep Cutting Prices To Win Back Market Share, But Demand Recovery Remains Uncertain</a></li>
</ul>
Photo by earthphotostock via Shutterstock

Health Care

Rhythm Pharmaceuticals Weight Loss Drug Study Shows Significant BMI Reduction For Rare Type Of Obesity Disorder

Rhythm Pharmaceuticals shares are trading higher after the company announced that the Phase 3 TRANSCEND trial met its primary endpoint.

<ul>
<li>Patients with acquired hypothalamic obesity on setmelanotide therapy (n=81) achieved mean BMI change of -16.5% compared with +3.3% for placebo (n=39) at 52 weeks.</li>
<li>19.2% placebo-adjusted BMI reduction achieved in adult patients 18 years old and older (n=49) at 52 weeks.</li>
<li>20.2% placebo-adjusted BMI reduction achieved in patients younger than 18 years old (n=71) at 52 weeks.</li>
<li>Regulatory submissions in the U.S. and EU anticipated to be completed in the third quarter of 2025.</li>
</ul>

Rhythm Pharmaceuticals' Phase 3 TRANSCEND Trial Of Setmelanotide For Acquired Hypothalamic Obesity, Met Its Primary Endpoint With Statistically Significant And Highly Clinically Meaningful Reduction In Body Mass Index In Adult And Pediatric Patients Versus Placebo

Reported Sunday, Rhythm Pharmaceuticals To Reveal Topline Results From Pivotal Phase 3 TRANSCEND Trial Of Setmelanotide In Acquired Hypothalamic Obesity

Press Releases

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration

Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan

Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd.

Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update

Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access Program

Comments

Rhythm Pharmaceuticals

空売り

Rhythm Pharmaceuticals (NASDAQ:RYTM) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル